Amneal ‘Hyper Focused’ On New Launches
As Generics Business Exceeds Expectations In The First Quarter
Aiming to “aggressively expand sales,” Amneal has announced that it will be launching 15 new generics by August 2021. Amneal’s generics business has also reported growth beyond its set targets for the first quarter of 2020.
You may also be interested in...
Following approval by the FDA, Amneal has launched a generic version of the Butrans buprenorphine transdermal system, immediately initiating commercialization activities across all strengths.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Amneal reported a 20% drop in sales in the fourth quarter of 2019, primarily due to lower turnover from its generics business. The company’s co-CEOs are trying to revitalize the company and have launched 15 new products since returning midway through last year.